ADVERSE DRUG REACTIONS Mary Teeling 27 April 2009.

Slides:



Advertisements
Similar presentations
Warfarin, Insulin and Digoxin are the most Dangerous drugs in the elderly. Do we believe that?
Advertisements

Pharmacovigilance, the MHRA and Yellow Cards Aileen McKenna Senior Clinical Pharmacist.
The management of adverse drug reactions I Ralph Edwards
Safety Reporting IN Clinical Trials
ADVERSE EVENT REPORTING
Pharmacovigilance Dr. Muiris Dowling,
Walsall Healthcare NHS Trust Medicines Management.
1 2 Why should I lose time to send a report of adverse drug reactions?
OPTIMISING MEDICINES USE GRAHAM DAVIES Professor of Clinical Pharmacy & Therapeutics Institute of Pharmaceutical Science King’s College London.
An ABC of Drug-Related Problems RHB Meyboom, M Lindquist, ACG Egberts Drug Safety 2000;22:
DR. SHABANA ALI. Adverse Drug Reactions (ADR) Harm associated with the use of a given medications OR Unwanted or harmful reaction experienced after the.
Basic Pharmacovigilance Training
Yasar Kucukardali Professor, Internal Medicine Yeditepe University.
1 Lotronex ® (alosetron HCl) Tablets Risk-Benefit Issues Victor F. C. Raczkowski, M.D. Director, Division of Gastrointestinal and Coagulation Drug Products.
Drug safety in the elderly EFNS Stockholm 2012 Barbro Westerholm Prof.em, Member of Swedish Parliament.
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications Mark Bleackley MEDG 505 March.
Requirements of EU pharmacovigilance legislation for distributors Julia Sipos Quality Management Director Pharmacovigilance coordinator Version 03.
SERIOUS ADVERSE EVENTS REPORTING Elizabeth Dayag IRB Administrator Naval Medical Center Portsmouth.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 11 Drug Therapy in Geriatric Patients.
Introduction to Precision Medicine
Template for study specific training for Intrapartum Research Studies [ Please see guide before using this]
Testing People Scientifically.  Clinical trials are research studies in which people help doctors and researchers find ways to improve health care. Each.
Adverse Events and Unanticipated Problems Presented by: Karen Jeans, PhD, CCRN, CIP COACH Program Analyst.
Clinical causality assessment I. Ralph Edwards R.H.B Meyboom.
MCA Risk:benefit analysis of Kava-kava Update as at 12 Feb 2002.
H. Lundbeck A/S21-Sep-151 Pharmacovigilance during clinical development SAE reporting, ASUR and PSUR IFF Seminar, 21. February 2007.
Collecting data in clinic.  Aim of BADBIR  Definition of Adverse Events  Adverse events in BADBIR  Adverse event recording in hospital case notes.
ADVERSE EFFECTS OF DRUGS Phase II May Adverse Drug Reaction An adverse reaction to a drug is a harmful or unintended response. ADRs are claimed.
PHARMACOVIGILANCE AND CLINICAL TRIALS DIVISION 20 August 2015 Victoria Falls Protecting Your Right to Quality Medicines and Medical Devices.
Reporting of Adverse Drug Reactions: a study among Clinicians
Background Collection of S & O Information Data: – CC, HPI, PMH, PSHx, Demographics – Medication history including compliance etc. – VS, ROS, Lab, other.
ICH V2 An FDA Update Susan Lu Office of Drug Safety Center for Drug Evaluation and Research FDA January 21, 2003.
Some Perspectives on a Draft Pharmacovigilance Protocol-reference to HIV/AIDS I Ralph Edwards.
CTD, Safety Tanja Braakman Genzyme Europe BV Pharmacovigilance Department.
Pharmacology 3 Safety and Effectiveness in Medicines Administration Applying the Evidence Base.
Problems of Polypharmacy
Author Name: Kannika Inpra Presenter Name: Kannika Inpra Authors: Inpra K., Suwankesawong W., Kaewvichit S. Institution: Phrae.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 2 Application of Pharmacology in Nursing Practice.
Joint Dermatologic and Ophthalmic Drugs & Drug Safety and Risk Management Advisory Committee February 26 & 27, 2004 RISK MANAGEMENT OPTIONS FOR PREGNANCY.
METHODS TO STUDY DRUG SAFETY PROBLEMS animal experiments clinical trials epidemiological methods –spontaneous reporting case reports case series –Post-Marketing.
Dr. Reneega Gangadhar Professor & Head Dept of Pharmacology Govt. T.D Medical college Alappuzha Pharmacovigilance.
Definitions. Clinical pharmacy is the branch of Pharmacy where pharmacists provide patient care that optimizes the use of medication and promotes health,
Technical Briefing Seminar September |1 | Methods to study medicine safety problems Mary R Couper Quality Assurance and Safety of Medicines.
EAE Training EAE Reporting and Assessment Overview DAIDS Regional Training Event, Regulatory Compliance Center Kampala, Uganda, September 2009 DAIDS Regional.
DRUG INTERACTIONS. –Adverse drug effects –Hypersensitivity –Anaphylactic reactions.
Good Pharmacovigilance Practices
Introduction.
Patient’s Medication Experience 1. Notes One of the important variables that if succeed it will affect in providing good pharmaceutical care. It is an.
Signal identification and development I.Ralph Edwards.
Postmarketing Pharmacovigilance Practice at FDA Lanh Green, Pharm.D., M.P.H. Office of Surveillance and Epidemiology June 21, 2006.
European Patients’ Academy on Therapeutic Innovation Introduction to pharmacovigilance Monitoring the safety of medicines.
Effets indesirables des médicaments Cours en partie basé sur source documentaire de l’OMS.
Pharmacogenomics: Improving the Dynamic of Care in Medication Management 1.
Medicines Act: Pharmacovigilance and the Medical Profession.
Medicines that interact with alcohol See “Guidance on the administration of medicines to inpatients believed to have consumed alcohol ”
REPORTING ADVERSE EVENTS AND COMPLETING THE REPORT FORM
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
ADR. EBM..
Assessing expectedness of an adverse event
8. Causality assessment:
3. Key definitions Multi-partner training package on active TB drug safety monitoring and management (aDSM) July 2016.
Pharmacovigilance in clinical trials
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
9. Introduction to signal detection
Pharmacovigilance (PV)
SERIOUS ADVERSE EVENTS REPORTING
Patient details Health number: this may be a national identifier (preferred), hospital, clinic, or program number Name: full name is preferable as an accurate.
Pharmacovigilance & Adverse Drug Reactions Dr. Habab Khalid Elkheir
Ramy Abdelrahman, MD Division of Pediatric and Maternal Health (DPMH)
Dr Tim England TICH-2 SAE adjudicator
Presentation transcript:

ADVERSE DRUG REACTIONS Mary Teeling 27 April 2009

Did you know that In U.S. ADRs cause an estimated 100,000 deaths per year Up to 5% of all hospital admissions are due to ADRs 30% of hospital patients suffer an ADR This is huge cause of iatrogenic disease.

What is meant by the term “Adverse Drug Reaction (ADR)?

Adverse (Drug) Reaction (ADR) Defined as: a response to a medicinal product which is noxious and unintended and which occurs at doses normally used in man for the prophylaxis, diagnosis or therapy of disease or the the restoration, correction or modification of physiological function. Not due to overdose or drug abuse Causal relationship between the drug and the response is suspected, but not necessarily proven

In plain english… An ADR is an unwanted, adverse occurrence (e.g. skin rash, GIT problems etc) in a patient which you suspect might be caused by a drug the patient has taken

Serious Adverse Drug Reaction Defined as: - Serious adverse reaction means an adverse reaction which results in death, is life- threatening, requires inpatient hospitalisation, or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a congenital anomaly / birth defect.

Unexpected ADR This is a suspected ADR that is not listed in the prescribing information ( Summary of Product Characteristics) of a medicine. NOT ALL ADRS ARE KNOWN ABOUT A DRUG AT TIME IT IS LICENSED

Adverse Event (AE) Defined as: - An undesirable experience occurring following administration of a “medicinal Product” An adverse event does not necessarily have a “causal relationship” with a medicine

Why do ADRs occur? Most ADR’s are Predictable i.e. based on pharmacological action of the drug Dose-dependent May be preventable / avoidable (“Type A” or “pharmacological” ADR’s make up 80% of ADRs)

Examples of Type A reactions Warfarin orExcessive Aspirin bleeding Beta blockers cold hands and feet Cytotoxic Agents Myelosuppression (anti-cancer)

Type B Reactions These may be known as “idiosyncratic” / “bizarre” These are not predictable from pharmacological action of drug often –serious –dose-independent may be immune-mediated (e.g. IgE mediated hypersensitivity reactions)

[Type C Reactions] Includes Increased rate of disease being treated with drug –arrhythmias with use of anti-arrhythmic agents –suicide in depressed patients on anti-depressants Increased rate of “spontaneous” disease in specific populations –increased rate of vaginal cancers in daughters of women who received stilboestrol during pregnancy – 20 year time lapse **Not predictable, often hard to detect but pharmacovigilance may pick them up eventually**

Pharmacogenomics This is the study of how an individual’s genetic inheritance affects his / her response to drugs Genetic polymorphisms of several enzyme systems have already been elucidated Affecting Cytochrome p450 systems (e.g.CYP2D6) Functional Enzymes (e.g. ACE) This may impact on development of ADRs in future - ?how

Risk factors for ADR’s Extremes of age Health status (liver/renal disease) Concomitant drug use (“polypharmacy”) Female gender (?) But remember ADR’s can occur in the absence of any of these!

What drugs cause ADR’s All drugs can! Important areas for prescriber: Drugs with a narrow TI / therapeutic index (cytotoxics, anti-epileptic agents) Most commonly used drugs (NSAIDs, Cardiac drugs – greater exposure) Drugs in combination (e.g. diuretics and digoxin, warfarin and NSAIDs)

How to diagnose ADR’s (1) Should include ADR in differential diagnosis of disease state (e.g. liver disease, skin rash, G.I. bleeding) Check out Drugs that patient has been prescribed Drugs that patient is actually taking! Clarify dose, dosing interval Always ask for OTC / herbal medicine (remedy) usage

How to diagnose ADR’s (2) Check out Exact nature of disease state / reaction Possible temporal relationship with drug exposure Past history of similar events with other / similar drugs Perform relevant laboratory tests (LFT’s, FBC and Blood film) “Dechallenge” versus “rechallenge” -??

How to manage ADR’s Serious Need to treat symptoms urgently (e.g. anaphylaxis) Need to discontinue drug Warn patient for future Non – serious Treat symptoms as appropriate Decision to withdraw depends on ADR, underlying disease, availability of alternative therapy (cytotoxics)

Question A 70-year old is knocked down by a car, 4 days after starting a new drug treatment for hypertension ? Is this an ADR or AE?

Answer Well it could be ADR! Did she stumble in front of the car due to hypotension / altered consciousness / ataxia / other CNS effects from the drug? Or was the driver at fault?

What to do with this lady (1) History of event very important as is history of how she has been since starting the medicine –Symptoms of postural hypotension –Feelings of unsteadiness –Any new / unusual symptoms since starting the drug –Does she remember the event

What to do with this lady (2) Check for hypotension / postural hypotension, any signs of unsteadiness Check the prescribing information for similar reports of unsteadiness etc Remember Just because it is not listed doesn’t mean that the drug is not to blame If in doubt report to the regulatory authorities

Reporting ADRs All suspected reactions can be reported (i.e. don’t need absolute certainty that this is an ADR) to the Remember Irish Medicines Board (IMB)? Responsible for collecting information on ADRs in Ireland from healthcare professionals and acting on the information as appropriate

Why Report ADRs? Part of Pharmacovigilance (defined as the ongoing monitoring of safety of medicines in the marketplace i.e. real-life usage in the interest of public health) ADR reporting (“spontaneous reporting”) invaluable for picking up previously unknown ADR’s i.e. not identified in clinical trials

Why Report ADRs? Can identify problems with faulty batches of biological or biotechnological medicines (remember HIV and HCV with blood products) Can identify hitherto unknown ADRs in special populations (e.g. our 70-year lady) Can identify hitherto unknown problems with teratogenicity / longterm ADRs **Type B & C reactions usually only identified by pharmacovigilance**

Remember: - Majority of ADRs are predictable and due to the pharmacological action of the drug Certain patient characteristics may predispose to ADRs Prescribing information on each drug gives details of contraindications and special precautions for use Pharmacogenomics may help to further elucidate susceptibility to ADRs in future

Sources of Information on ADRs Irish Medicines Board Prescribing information (Summaries of Product Characteristics) at National Medicines Information Centre

Questions?